Overview
You can access the company’s website by clicking here.
Fundamentals
Price
News
-
30 Aug 2018 2 min read
IP Group-backed Genomics raises £25m in a Series B
IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals. Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]
-
27 Jun 2018 1 min read
IP Group investee Carisma Therapeutics closes $53m fundraising
IP Group investee Carisma Therapeutics closes $53m fundraising Carisma Therapeutics, a US-based investee company for LSE-listed IP Group (IPO), has closed a $53m series A fundraising. The financing was led by AbbVie Ventures, the corporate venture arm of the US pharmaceutical giant, and HealthCap, an EU VC investor, and included the existing seed investors, IP Group, Penn […]
-
06 Feb 2017 3 min read
Henderson Opportunities struggles in difficult year for small caps
Henderson Opportunities says its Net Asset Value total return for the year ended 31 October 2016 was 0.4%, while the UK market returned 12.2%. Its discount widened significantly over the course of the year, to stand at 17.5% at the year end. The total dividend for the year is 19.00p an increase of 5.6% on the previous year. The […]
-
29 Jul 2016 2 min read
Law Debenture swaps Henderson OEICs for Scottish Oriental Smaller Companies
Law Debenture says its Net Asset Value total return for the six months to 30 June 2016 was 1.5%, compared to a total return of 4.3% for the FTSE Actuaries All-Share Index. Most of this underperformance arose from the movement in fair value of our long term debt as a result of lower gilt yields. […]
-
22 Jun 2016 3 min read
Henderson Opportunities suffers as large cap outperforms
Henderson Opportunities Trust has published interim figures covering the six months ended 30 April 2016. The company’s net asset value fell by 2.4% over the period, while the FTSE All Share Total Return ( the benchmark) remained flat. The share price fell by 8.8%, which was more than the NAV. At the end of April the […]
